In NSCLC patients, somatic mutations in EGFR gene, most commonly deletions in exon 19 (delE746-A750) or substitution of arginine for leucine (L858R) in exon 21, are observed in ∼10% of cases in North America and Western Europe, and ∼30–50% in East Asian descent [4–6]. Here, EGFR is linked to non-small cell lung carcinoma.